1. Academic Validation
  2. Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action

  • Angew Chem Int Ed Engl. 2022 Jun 20;61(25):e202204052. doi: 10.1002/anie.202204052.
Tobias Mühlethaler 1 Lampros Milanos 2 Jose Antonio Ortega 2 Thorsten B Blum 1 Dario Gioia 2 Bibhas Roy 3 Andrea E Prota 1 Andrea Cavalli 2 4 Michel O Steinmetz 1 5
Affiliations

Affiliations

  • 1 Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland.
  • 2 Computational & Chemical Biology, Istituto Italiano di Tecnologia, via Morego 30, 16163, Genova, Italy.
  • 3 Laboratory of Nanoscale Biology, Department of Biology and Chemistry, Paul Scherrer Institut, 5232, Villigen PSI, Switzerland.
  • 4 Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna, via Belmeloro 6, 40126, Bologna, Italy.
  • 5 University of Basel, Biozentrum, 4056, Basel, Switzerland.
Abstract

In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved-to-straight conformational switch in the α-tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin-binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.

Keywords

Fragments; Microtubule-Targeting Agents; Molecular Mechanism of Action; Rational Drug Design; Tubulin.

Figures
Products